Patents by Inventor Qizhi MA

Qizhi MA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically engineered dual-targeting chimeric antigen receptor and use thereof
    Patent number: 12281164
    Abstract: The present invention belongs to the field of genetic engineering, and particularly relates to a genetically engineered dual-targeting chimeric antigen receptor. The present invention provides a genetically engineered dual-targeting chimeric antigen receptor and a host cell thereof in response to up-regulated expression of PD-L1 in tumor cells and immune cells after these cells are exposed to malignant serosal cavity effusion. The dual-targeting chimeric antigen receptor provided by the present invention competitively binds to PD-L1 to transform an inhibition signal of PD-L1 into an activation signal and to enhance the killing activity of T cells; meanwhile, 4-1BB introduced downstream thereof can promote proliferation and survival of T cells. In addition, the present invention also discloses a host cell expressing the above dual-targeting antigen receptor and a use thereof in preventing or treating solid tumors.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: April 22, 2025
    Assignee: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
    Inventors: Yongsheng Wang, Qizhi Ma, Dan Li, Qiyu Yang
  • GENETICALLY ENGINEERED DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
    Publication number: 20220185893
    Abstract: The present invention belongs to the field of genetic engineering, and particularly relates to a genetically engineered dual-targeting chimeric antigen receptor. The present invention provides a genetically engineered dual-targeting chimeric antigen receptor and a host cell thereof in response to up-regulated expression of PD-L1 in tumor cells and immune cells after these cells are exposed to malignant serosal cavity effusion. The dual-targeting chimeric antigen receptor provided by the present invention competitively binds to PD-L1 to transform an inhibition signal of PD-L1 into an activation signal and to enhance the killing activity of T cells; meanwhile, 4-1BB introduced downstream thereof can promote proliferation and survival of T cells. In addition, the present invention also discloses a host cell expressing the above dual-targeting antigen receptor and a use thereof in preventing or treating solid tumors.
    Type: Application
    Filed: November 12, 2019
    Publication date: June 16, 2022
    Inventors: Yongsheng WANG, Qizhi MA, Dan LI, Qiyu YANG